Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?

Hepatology. 2007 Jul;46(1):283; author reply 283-4. doi: 10.1002/hep.21707.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Anemia / chemically induced*
  • Anemia / drug therapy*
  • Antiviral Agents / economics
  • Antiviral Agents / therapeutic use*
  • Cost-Benefit Analysis
  • Drug Therapy, Combination*
  • Erythropoietin / economics
  • Erythropoietin / therapeutic use*
  • Humans

Substances

  • Antiviral Agents
  • Erythropoietin